Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$62.00
$46.56
$10.14
$66.94
$1.57B1.18548,054 shs344,502 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$7.46
-5.0%
$8.73
$5.03
$13.48
$396.54M1.11609,434 shs659,357 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$17.28
+2.0%
$15.49
$8.31
$25.29
$1.51B0.741.39 million shs1.14 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$27.63
+7.8%
$34.40
$24.28
$55.33
$1.55B2.361.45 million shs2.55 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
0.00%-0.74%+22.70%+220.25%+424.98%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-4.97%-10.44%-14.06%-8.80%-36.13%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+2.01%+8.27%+4.92%-17.48%+102.58%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+7.76%-8.54%-27.35%-14.43%-37.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.3759 of 5 stars
2.62.00.04.62.71.70.0
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
3.9625 of 5 stars
3.41.00.04.61.53.30.6
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.0404 of 5 stars
3.41.00.00.03.20.80.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.5616 of 5 stars
3.40.00.04.43.10.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.11
Buy$64.143.46% Upside
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.83
Moderate Buy$28.38280.36% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.2186.43% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4078.79% Upside

Current Analyst Ratings Breakdown

Latest RGNX, CDTX, TWST, and TVTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$59.00 ➝ $66.00
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00 ➝ $74.00
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $74.00
8/8/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $17.00
8/8/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $37.00
8/8/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $31.00
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$30.00 ➝ $32.00
(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$1.27M1,238.05N/AN/A$14.92 per share4.16
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$83.33M4.52N/AN/A$5.24 per share1.42
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M6.61N/AN/A$0.76 per share22.74
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M5.33N/AN/A$8.07 per share3.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$169.83M-$11.13N/AN/AN/AN/A-83.52%-61.76%N/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$227.10M-$3.44N/AN/AN/A-112.70%-66.95%-34.14%N/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%N/A

Latest RGNX, CDTX, TWST, and TVTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$1.87-$1.65+$0.22-$1.65N/AN/A
8/7/2025Q2 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$1.13-$1.38-$0.25-$1.38$40.87 million$21.36 million
8/6/2025Q2 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
5/12/2025Q1 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$0.41$0.12-$0.29$0.12$105.35 million$89.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.87
3.87
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
3.13
3.13
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.50
2.00
1.98
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60

Institutional Ownership

CompanyInstitutional Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
7.64%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
12.79%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.06%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9025.36 million23.42 millionNo Data
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37050.51 million44.05 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46089.14 million85.52 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable

Recent News About These Companies

FY2025 Earnings Estimate for TWST Issued By Leerink Partnrs
Twist Bioscience (TWST) Q3 Profit Surges
Twist Bioscience Corporation (NASDAQ:TWST) Short Interest Update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$62.00 0.00 (0.00%)
Closing price 08/11/2025 04:00 PM Eastern
Extended Trading
$63.85 +1.85 (+2.98%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$7.46 -0.39 (-4.97%)
Closing price 08/11/2025 04:00 PM Eastern
Extended Trading
$7.47 +0.01 (+0.13%)
As of 08/11/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$17.28 +0.34 (+2.01%)
Closing price 08/11/2025 04:00 PM Eastern
Extended Trading
$17.62 +0.34 (+1.96%)
As of 04:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$27.63 +1.99 (+7.76%)
Closing price 08/11/2025 04:00 PM Eastern
Extended Trading
$27.40 -0.23 (-0.84%)
As of 05:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.